IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
Zhang, Hongyan1; Li, Huafang2; Shu, Liang1; Gu, Niufan2; Wang, Gang3; Weng, Yongzhen3; Xie, Shiping4; Zhang, Xinbao4; Li, Ting5; Ma, Cui5; Yu, Wei6; Parsons, Bruce7; Schou, Manjula8
关键词Ziprasidone Risperidone Schizophrenia
刊名NEUROPSYCHIATRIC DISEASE AND TREATMENT
2011
DOI10.2147/NDT.S16664
7页:77-85
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology ; Psychiatry
研究领域[WOS]Neurosciences & Neurology ; Psychiatry
关键词[WOS]PLACEBO-CONTROLLED TRIAL ; SCHIZOAFFECTIVE DISORDER ; NEUROLEPTIC DOSAGE ; HALOPERIDOL ; EFFICACY ; MULTICENTER ; TOLERABILITY ; OLANZAPINE ; CLOZAPINE ; INPATIENTS
英文摘要

Background: The aim of the study was to evaluate the efficacy and safety of ziprasidone versus risperidone in Chinese subjects with acute exacerbation of schizophrenia.

Methods: In patients meeting the Chinese Classification of Mental Disorders criteria for schizophrenia and with a Positive and Negative Syndrome Scale (PANSS) total score >= 60 were randomly assigned to six weeks of double-blind treatment with ziprasidone 40-80 mg twice daily or risperidone 1-3 mg bid, flexibly dosed. Noninferiority was demonstrated if the upper limit of the two-sided 95% confidence interval (CI) for the difference in PANSS total score improvement from baseline in the evaluable population was smaller than the prespecified noninferiority margin of 10 units.

Results: The intent-to-treat population comprised 118 ziprasidone-treated and 121 risperidone-treated subjects. Improvement (reduction) from baseline to week 6 in PANSS total score was (-35.6 [95% CI: -38.6, -32.6]) for ziprasidone and (-37.1 [95% CI: -39.9, -34.4]) for risperidone. Noninferiority was demonstrated in the evaluable population with a difference score of 1.5 [95% CI: -2.5, 5.5]. Mean prolactin levels decreased at week 6 compared with baseline for ziprasidone (-3.5 ng/mL), but significantly increased for risperidone (61.1 ng/mL; P < 0.001). More risperidone-treated subjects (14.9%) than ziprasidone-treated subjects (4.2%) reported weight gain >= 7%. Akathisia and somnolence in the ziprasidone group and akathisia and insomnia in the risperidone group were the most common side effects. Treatment-related/treatment-emergent adverse events were reported by 79.7% and 71.1% of ziprasidone-treated and risperidone-treated subjects, respectively.

Conclusion: In Chinese subjects, ziprasidone was as effective as risperidone, with less weight gain and less prolactin elevation.

语种英语
WOS记录号WOS:000294955100009
资助机构Pfizer Inc.
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/49922
专题北京大学精神卫生研究所
北京大学医学图书馆_采访编目部
作者单位1.Peking Univ, Dept Psychiat, Inst Mental Hlth, Beijing 100191, Peoples R China
2.Shanghai Mental Hlth Ctr, Shanghai, Peoples R China
3.Capital Med Univ, Beijing An Ding Hosp, Beijing, Peoples R China
4.Nanjing Brain Hosp, Nanjing, Peoples R China
5.Guangzhou Brain Hosp, Guangzhou, Guangdong, Peoples R China
6.Pfizer China, Beijing, Peoples R China
7.Pfizer Inc, New York, NY USA
8.Pfizer Australia, Sydney, NSW, Australia
推荐引用方式
GB/T 7714
Zhang, Hongyan,Li, Huafang,Shu, Liang,et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia[J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT,2011,7:77-85.
APA Zhang, Hongyan.,Li, Huafang.,Shu, Liang.,Gu, Niufan.,Wang, Gang.,...&Schou, Manjula.(2011).Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia.NEUROPSYCHIATRIC DISEASE AND TREATMENT,7,77-85.
MLA Zhang, Hongyan,et al."Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia".NEUROPSYCHIATRIC DISEASE AND TREATMENT 7(2011):77-85.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Hongyan]的文章
[Li, Huafang]的文章
[Shu, Liang]的文章
百度学术
百度学术中相似的文章
[Zhang, Hongyan]的文章
[Li, Huafang]的文章
[Shu, Liang]的文章
必应学术
必应学术中相似的文章
[Zhang, Hongyan]的文章
[Li, Huafang]的文章
[Shu, Liang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。